TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Laekna, Inc. ( (HK:2105) ) has issued an announcement.
Laekna, Inc. has submitted an Investigational New Drug application to the U.S. FDA for LAE103, a monoclonal antibody aimed at treating sarcopenic obesity and muscle-related diseases. This move signifies the company’s commitment to developing precision therapies for metabolic patients, potentially enhancing its position in the biotechnology sector.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.46 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. operates in the biotechnology industry, primarily focusing on the development of innovative therapies for metabolic diseases. The company is engaged in advancing monoclonal antibodies, such as LAE103, targeting conditions like sarcopenic obesity and muscle-related diseases.
Average Trading Volume: 4,708,100
Technical Sentiment Signal: Strong Buy
See more data about 2105 stock on TipRanks’ Stock Analysis page.